Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067763 | 1.00 | ACE (0.41) | ACEITGB3ITGA2BDPP4 | |
| SCHEMBL18067761 | 0.92 | ACE (0.33) | ACEITGB3DPP4 | |
| SCHEMBL18067759 | 0.92 | ACE (0.33) | ACEITGB3DPP4 | |
| SCHEMBL18067766 | 0.81 | ACE (0.43) | ACEITGB3ITGA2BDPP4 | |
| SCHEMBL18067764 | 0.81 | ACE (0.43) | ACEITGB3ITGA2BDPP4 | |
| SCHEMBL24827499 | 0.78 | ACE (0.46) | ACEDPP4 | |
| SCHEMBL9256919 | 0.76 | ACE (0.35) | ACEDPP4 | |
| SCHEMBL18067762 | 0.71 | PIK3CD (0.37) | ACEDPP4 | |
| SCHEMBL18067760 | 0.71 | PIK3CD (0.37) | ACEDPP4 | |
| SCHEMBL9252755 | 0.71 | PIK3CD (0.37) | ACEDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | ITGB1, ITGA1, ITGAV | ACE 1444/4885ITGB3 7/4885ITGA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.